Topics

Glioblastoma | Treatment | Immunotherapy | Rivolumab

Home > Publications > Topics > Glioblastoma > Treatment > Immunotherapy > Rivolumab

*Hendriksen JD, Locallo A, Maarup S, Debnath O, Ishaque N, Hasselbach B, Skjøth-Rasmussen J, Yde CW, Poulsen HS, Lassen U, Weischenfeldt J.
Immunotherapy drives mesenchymal tumour cell state shift and TME immune response in glioblastoma patients.
Neuro Oncol. 2024 May 2:noae085. doi: 10.1093/neuonc/noae085. PMID: 38695342. Observational study˰ ˍ

Alan O, Bulbul MC, Enlice MA, Mandel NM.
Immunotherapy-related secondary hemophagocytosis in a glioblastoma patient: response to cytokine-directed therapy.
Immunotherapy. 2025 Jan 15:1-7. doi: 10.1080/1750743X.2025.2451604. PMID: 39812468. Case report˰ ˍ